BRCA1 and cancer: Inhibition of PARP1 in BRCA1- or BRCA2-deficient cancer cells leads to synthetic lethality, because these mutant cells rely on PARP1 for blocking cellular accumulation of catastrophic DSBs31, 32, 33, 34.